| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | LLY | Common Stock | Sale | -$5.78M | -7.06K | -21.72% | $819.38 | 25.4K | Jun 3, 2024 | Direct | F1, F2 |
| holding | LLY | Common Stock | 402 | Jun 3, 2024 | 401(k) | ||||||
| holding | LLY | Common Stock | 1.77K | Jun 3, 2024 | 401(k) - by partner | F3 | |||||
| holding | LLY | Common Stock | 128 | Jun 3, 2024 | by partner | F3 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2024. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $818.80 to $819.59, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. |